MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Inventory
Raw materials, work in progress, and finished goods held for sale.
MDxHealth S.A.NASDAQ: MDXH
{ "id": "headlineBalanceRises", "params": { "change": { "type": "change", "value": 75.86112629852379 } } }
[ { "id": "balanceUp", "params": { "amount": { "type": "amount", "value": 6433000 }, "period": { "type": "period", "period": { "kind": "quarter", "fiscalYear": 2026, "fiscalQuarter": 2 } }, "change": { "type": "change", "value": 75.86112629852379 } } }, { "id": "longRunCompounded", "params": { "years": { "type": "count", "value": 3 }, "change": { "type": "signedChange", "value": 42.55287523585751 } } } ]
Context
- { "id": "shareOfAssetsUp", "params": { "share": { "type": "share", "value": 0.04870311766576321 }, "period": { "type": "period", "period": { "kind": "quarter", "fiscalYear": 2026, "fiscalQuarter": 2 } }, "points": { "type": "points", "value": 2.2692152956200022 } } }
- { "id": "streakIncreased", "params": { "rises": { "type": "count", "value": 3 }, "years": { "type": "count", "value": 3 } }, "count": 3 }
- { "id": "extremeHighestFigure", "params": { "fiscalYear": { "type": "fiscalYear", "value": 2025 }, "years": { "type": "count", "value": 4 } } }
What to watch
{ "id": "watchBalanceRising", "params": { "change": { "type": "signedChange", "value": 75.86112629852379 } } }
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 6.74M USD
- Year-over-year change
- +74.2%
- 4-year CAGR
- +37.0%
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.74M | +74.2% |
| FY2024 | 2024-12-31 | 3.87M | +39.2% |
| FY2023 | 2023-12-31 | 2.78M | +19.4% |
| FY2022 | 2022-12-31 | 2.33M | +21.8% |
| FY2021 | 2021-12-31 | 1.91M | — |
Inventory vs competitors
How MDXH compares with its peers on the latest reported figures
- { "id": "valueRankMedian", "params": { "ticker": { "type": "text", "value": "MDXH" }, "period": { "type": "peerPeriod", "period": { "kind": "quarterEnd", "date": "2026-06-30" } }, "amount": { "type": "amount", "value": 6433000 }, "rank": { "type": "rank", "position": 5, "total": 11, "direction": "high", "bySize": false }, "count": { "type": "count", "value": 11 }, "median": { "type": "amount", "value": 2951500 } } }
- { "id": "yoyRankMedian", "params": { "change": { "type": "signedChange", "value": 75.86112629852379 }, "rank": { "type": "rank", "position": 1, "total": 6, "direction": "high", "bySize": false }, "count": { "type": "count", "value": 6 }, "median": { "type": "signedChange", "value": 8.172988821696903 } } }
- { "id": "shareOfAssetsMedian", "params": { "ticker": { "type": "text", "value": "MDXH" }, "share": { "type": "share", "value": 0.04870311766576321 }, "median": { "type": "share", "value": 0.010034069320381027 } } }
| Company | Period | YoY | 3-year CAGR | |
|---|---|---|---|---|
| — | $50.96M | +64.2% | +47.8% | |
| — | $27.14M | -20.6% | +5.6% | |
| — | $21.83M | +66.6% | — | |
| — | $10.5M | +7.0% | +6.7% | |
| — | $6.43M | +75.9% | +42.6% | |
| — | $5.9M | +8.2% | +89.8% | |
| — | $0 | — | — | |
| — | $0 | — | — | |
ZURAZura Bio Limited | — | $0 | — | — |
| — | $0 | — | — | |
| — | $0 | — | — | |
| Peer median (excluding MDXH) | $2.95M | +8.2% | +27.2% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58.5M | 15.5M | 22.38M | 46.8M | 29.03M |
| Short-term Investments | 89K | 101K | 0 | 0 | 0 |
| Net Receivables | 4.58M | 9.36M | 11.27M | 14.53M | 14.73M |
| Inventory | 1.91M | 2.33M | 2.78M | 3.87M | 6.74M |
| Other Current Assets | 504K | 151K | 146K | 135K | 940K |
| Total Current Assets | 66.61M | 29.15M | 38.16M | 66.9M | 53.41M |
| Property, Plant & Equipment (Net) | 5.02M | 7.89M | 9.95M | 12.98M | 14.68M |
| Goodwill | 0 | 35.93M | 35.93M | 35.93M | 38.95M |
| Intangible Assets | 3.45M | 46.17M | 44.34M | 40.59M | 39.42M |
| Long-term Investments | 0 | 0 | 763K | 936K | 1.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 8.47M | 89.99M | 90.97M | 90.43M | 94.54M |
| Total Assets | 75.07M | 119.14M | 129.13M | 157.33M | 147.95M |
| Account Payables | 7.46M | 10.18M | 8.81M | 8M | 10.33M |
| Short-term Debt | 4.44M | 616K | 643K | 324K | 1.9M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 472K | 0 | 0 |
| Other Current Liabilities | 961K | 2.33M | 2.9M | 26.41M | 37.31M |
| Total Current Liabilities | 16.43M | 18.28M | 19.52M | 42.66M | 49.53M |
| Long-term Debt | 7.65M | 34.91M | 35.56M | 50.97M | 84.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.47M | 53.54M | 63.26M | 41.45M | 17.3M |
| Total Non-current Liabilities | 11.74M | 91.54M | 102.4M | 99.83M | 110.51M |
| Total Liabilities | 28.17M | 109.82M | 121.92M | 142.49M | 160.05M |
| Common Stock | 143.42M | 148.42M | 173.93M | 214.67M | 219.21M |
| Retained Earnings | (244.3M) | (288.35M) | (331.45M) | (369.52M) | (403.03M) |
| Accumulated OCI | (5.4M) | (3.94M) | 11.55M | (615K) | 18.55M |
| Other Stockholders Equity | 0 | 0 | 0 | 17.12M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 46.9M | 9.32M | 7.21M | 14.84M | (12.09M) |
| Total Debt | 15.56M | 39.79M | 41.27M | 60.06M | 95.11M |
| Net Debt | (42.94M) | 24.29M | 18.89M | 13.27M | 66.08M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.